Nijmegen Breakage Syndrome-Like Disorder (RAD50 Deficiency): Comprehensive Research Report

1. Disease Information

Overview. Nijmegen breakage syndrome-like disorder (NBSLD) is an ultra-rare autosomal recessive chromosomal-instability syndrome caused by biallelic pathogenic variants in RAD50, which encodes the structural ATPase core of the MRE11–RAD50–NBS1 (MRN) DNA double-strand-break (DSB) sensing/repair complex. It is the clinical and molecular "sibling" of classic Nijmegen breakage syndrome (NBS, caused by NBN mutations) and ataxia-telangiectasia-like disorder (ATLD, caused by MRE11A mutations) — together the three MRN-complex genetic diseases. NBSLD is defined by severe pre- and postnatal growth failure, congenital/progressive microcephaly, mild-to-borderline intellectual disability, radioresistant DNA synthesis, and spontaneous chromosomal instability, but characteristically lacks the severe combined immunodeficiency and high cancer predisposition that define classic NBS (OMIM: "Nijmegen breakage syndrome-like disorder; NBSLD" OMIM:613078). It is exceptionally rare: fewer than ten molecularly confirmed patients/families have been reported worldwide as of 2026 (Weemaes 1981 [clinical description predating molecular diagnosis]; Waltes et al. 2009 [PMID:19409520]; Chansel-Da Cruz et al. 2020; Ragamin et al. 2020 [PMID:32449290]; Takagi/Kanegane et al. 2023; a 2026 Chinese case; a 2026 Frontiers in Endocrinology growth-hormone case report).

Key identifiers: - OMIM: #613078 (disorder); *604040 (RAD50 gene) - Orphanet: ORPHA240760 (contrasted with classic NBS, ORPHA647) - MONDO: MONDO:0013118 - MedGen/UMLS concept: C2751318 (NCBI MedGen) - Gene: RAD50, HGNC:9816, NCBI Gene ID 10111, chromosome 5q31.1 - ICD-10/11: No dedicated code exists; typically coded under Q87.8 (other specified congenital malformation syndromes) or grouped with chromosome-instability syndromes - MeSH: Indexed under the broader "DNA Repair-Deficiency Disorders" / "Chromosome Breakage Syndromes" headings; no dedicated MeSH descriptor

Synonyms: NBS-like disorder; NBSLD; RAD50 deficiency; NBS2 (informal); "Nijmegen breakage syndrome 2" (non-standard, avoid confusion with NBS itself).

Evidence basis: All current knowledge derives from individual, molecularly confirmed case reports (n≈6–9 patients across ~6 publications) rather than aggregated registries or large cohort studies — a critical distinction from classic NBS, for which the Slavic-population founder mutation has generated a >130-patient international registry (Frontiers in Immunology, 2020, PMC7819964). Prevalence estimates for NBSLD are therefore extrapolated as "<1 in 1,000,000" by OMIM/Orphanet rather than measured directly.

2. Etiology

Disease causal factor: NBSLD is purely monogenic/Mendelian — biallelic (homozygous or compound heterozygous) loss-of-function or hypomorphic variants in RAD50 are necessary and sufficient to cause disease. There is no known environmental, infectious, or multifactorial contribution to primary disease causation.

Genetic risk factors: - Causal variants (biallelic, required): Reported alleles include: - A maternally inherited nonsense mutation + paternally inherited stop-codon readthrough mutation causing a 66-amino-acid C-terminal protein extension (Waltes et al. 2009, PMID:19409520) - Homozygous c.2524G>A (splice donor disruption at the final base of exon 15), producing a major transcript with exon 15 skipping → frameshift (p.Met800Phefs7) and a minor transcript with a missense change (p.Val842Ile) (Ragamin et al. 2020, PMC7318339) - RAD50 E1035Δ — an in-frame single-amino-acid deletion in the coiled-coil domain, acting as a "separation-of-function" allele (Chansel-Da Cruz et al. 2020, PMC7788285) - Compound heterozygous c.3806_3807del (p.His1269Argfs*2) + c.2531G>A (p.Ser844Asn), both classified VUS, in a 2026 Chinese case (ScienceDirect, S037811192600051X) - Two distinct compound-heterozygous variants in a patient with bone-marrow failure/immunodeficiency features (Takagi/Kanegane 2023, J Clin Immunol, DOI:10.1007/s10875-023-01591-8) - Zygosity: Both homozygous (typically in consanguineous families) and compound heterozygous configurations reported. - Modifier/susceptibility (distinct condition, not NBSLD): Monoallelic (heterozygous) RAD50 variants are instead studied as cancer-susceptibility alleles — e.g., RAD50 c.687delT is a low-penetrance breast-cancer risk allele in the Finnish population (PMC3006189), and RAD50 zinc-hook-domain LoF variants confer familial esophageal squamous cell carcinoma risk (PMC8472384). A 2024 systematic review/meta-analysis found no significantly increased breast cancer risk for most RAD50 heterozygous pathogenic variants overall (OR 0.93, 95% CI 0.74–1.16), with c.687del as a specific exception (onlinelibrary.wiley.com/doi/full/10.1002/ijc.35066). - Founder effects:* None established for RAD50-NBSLD (contrast with the well-characterized NBN c.657_661del5 Slavic founder mutation for classic NBS, carrier frequency 0.5–1%, PMC5148078/PMC7819964). Each NBSLD family reported to date carries private/novel variants.

Environmental risk factors: None identified as causal. Ionizing radiation is not a cause but is a major secondary hazard given cellular radiosensitivity (see Diagnostics/Prevention).

Protective factors: None specifically described for NBSLD. By analogy to RAD50 heterozygosity literature, monoallelic carriers are generally asymptomatic carriers, not protected individuals.

Gene-environment interactions: The defining cellular gene-environment interaction is radiosensitivity — RAD50-deficient cells fail to arrest DNA synthesis after ionizing radiation exposure ("radioresistant DNA synthesis," RDS) due to defective ATM-dependent checkpoint signaling, making diagnostic/therapeutic radiation exposure disproportionately genotoxic in these patients (multiple sources below).

3. Phenotypes

Phenotypes are drawn from the ~6 reported cases; frequencies below are counts observed across the small case series (not population-level percentages) and should be read as qualitative/case-count "frequency," per Orphanet and OMIM clinical synopsis language.

Quality-of-life impact: No formal QoL instrument (EQ-5D/SF-36) data exist for this ultra-rare disease. Reported functional impact centers on growth failure requiring endocrine evaluation, hearing loss requiring amplification, and developmental/learning support; notably, unlike classic NBS, no reported neurodegeneration or decline in intellectual/motor function over time in the two best-characterized patients ("no decline of intellectual or motor functions has been observed").

4. Genetic/Molecular Information

Causal gene: RAD50 (RAD50 double-strand break repair protein), OMIM *604040, HGNC:9816, chr 5q31.1, NCBI Gene 10111.

Gene/protein function: RAD50 is a structural-maintenance-of-chromosomes (SMC)-family ATPase that, together with MRE11 and NBS1, forms the MRN complex — among the earliest sensors of DNA double-strand breaks. RAD50 uses its ABC-type ATPase domain, a Zn-hook dimerization motif, and long antiparallel coiled-coils to bridge broken DNA ends, gate MRE11 nuclease access for 5′→3′ end resection, tether sister chromatids, and license ATM kinase activation for checkpoint signaling (PMC4494100; GeneCards RAD50).

Pathogenic variant classes reported in NBSLD: - Nonsense/truncating: classic LoF, near-complete loss of protein - Stop-codon readthrough (extension) mutations: abnormal C-terminal extension impairing folding/stability - Splice-site disruption: e.g., c.2524G>A causing exon-15 skipping/frameshift, with a minor missense-producing transcript as a partial "leaky" allele - In-frame single-residue deletion (separation-of-function): RAD50 E1035Δ in the coiled-coil domain — selectively impairs DNA end resection/HR/replication-fork function while sparing ATM-dependent checkpoint signaling, illustrating that NBSLD's clinical spectrum can fractionate along distinct MRN sub-functions (PMC7788285) - Compound heterozygous frameshift + missense (VUS): e.g., c.3806_3807del + c.2531G>A in the 2026 Chinese case, with the frameshift allele shown by Western blot to destabilize RAD50 protein

Variant classification: Most reported variants are classified pathogenic/likely pathogenic per ACMG/AMP given segregation, protein-loss functional data, and de novo absence in gnomAD; two recent Chinese-case variants remain formally VUS pending further functional confirmation.

Allele frequency: RAD50 loss-of-function alleles are individually ultra-rare in population databases — e.g., the Ragamin et al. splice variant had a minor allele frequency of only 1.072×10⁻⁴ in gnomAD, observed only in heterozygous state (consistent with a rare, non-founder recessive allele).

Somatic vs. germline: All NBSLD-causing variants are constitutional/germline. (Somatic RAD50 alterations are separately studied in sporadic cancers via COSMIC/TCGA but are not part of this Mendelian disease.)

Functional consequences at the protein/cellular level: - Near-undetectable RAD50 protein by Western blot in patient fibroblasts, with secondary reduction of MRE11 and NBS1 protein levels (complex destabilization) — "RAD50 protein was almost undetectable in the F583 fibroblasts," with a "more pronounced reduction than previously reported" in the first patient (PMC7318339) - Failure of DNA-damage-induced MRN nuclear focus formation - Impaired ATM autophosphorylation and downstream substrate phosphorylation (CHK2 pSer19, KAP1/TRIM28 pSer824) after irradiation — "barely detectable at 6 Gy" - Radioresistant DNA synthesis (failure of the intra-S-phase checkpoint) mimicking ataxia-telangiectasia cells - Chromosomal instability in metaphase spreads (variable — one patient had a normal karyotype despite RDS, showing phenotypic/cytogenetic dissociation across alleles)

Modifier genes: None specifically established for NBSLD; by extension from MRN biology, TP53/ATM pathway status could theoretically modulate cellular phenotype but this is not documented in patients.

Epigenetic information: No disease-specific DNA methylation/chromatin studies have been published for RAD50-NBSLD specifically (contrast with broader MRN-complex chromatin-remodeling literature, PMID:17713585).

Chromosomal abnormalities: NBSLD is not a copy-number/structural chromosomal disorder — it is a sequence-level Mendelian gene defect that secondarily produces acquired chromosomal instability (translocations, breaks) as a cellular biomarker, not a germline CNV.

5. Environmental Information

• Environmental factors: Not causal, but critically relevant to iatrogenic risk: diagnostic/therapeutic ionizing radiation (X-ray, CT) poses disproportionate genotoxic/carcinogenic risk in RAD50-deficient patients due to radiosensitivity and impaired DSB repair; MRI and ultrasound are preferred alternatives (per management recommendations extrapolated from NBS and stated explicitly by Ragamin et al. 2020).
• Lifestyle factors: No specific lifestyle risk-modifying data published (disease is congenital/genetic, onset neonatal).
• Infectious agents: Not implicated in causation. Because immunodeficiency is largely (though not universally) absent in NBSLD — unlike classic NBS — recurrent infection susceptibility is not a defining environmental interaction, except in the minority of reported patients with bone-marrow failure/immunologic involvement (Takagi 2023; Chansel-Da Cruz 2020), where infection risk parallels that of primary immunodeficiency generally.

6. Mechanism / Pathophysiology

Causal chain (trigger → clinical manifestation):

1. Molecular trigger: Biallelic RAD50 variants → loss/destabilization of RAD50 protein → destabilization of the entire MRN (MRE11-RAD50-NBS1) complex (secondary reduction of MRE11 and NBS1 protein even though those genes are wild-type).
2. Cellular DSB-sensing failure: Loss of MRN focus formation at DNA double-strand breaks → failure to recruit and activate ATM kinase → loss of ATM-dependent phosphorylation cascade (CHK2, KAP1/TRIM28, and other substrates) → failure of the intra-S-phase checkpoint, manifesting as radioresistant DNA synthesis.
3. Genome instability: Impaired DSB end-resection (MRE11 nuclease access gated by RAD50 ATPase cycling) → defective homologous recombination repair → spontaneous and radiation-induced chromosomal instability (breaks, rearrangements) in some alleles; separation-of-function alleles (e.g., E1035Δ) show this resection/HR defect can be dissociated from the ATM-signaling defect, since ATM signaling and G2/M checkpoint remained intact in that patient despite defective resection.
4. Developmental consequence: Chronic replication stress and genome instability during embryonic/fetal neurodevelopment and somatic growth are hypothesized (by analogy to NBS/ATLD/microcephaly-primary genes) to drive severe growth failure and progressive microcephaly, likely reflecting impaired proliferation and increased apoptosis of neural progenitor and other rapidly dividing cell pools — the same final-common mechanism invoked broadly for "microcephaly-DNA repair" disorders.
5. Divergence from NBS/ATLD: Because RAD50 hypomorphic alleles in reported patients retain partial complex function (unlike complete NBS1 or MRE11 loss), the downstream immune and oncogenic consequences are attenuated in most patients — plausibly because sufficient residual MRN activity supports V(D)J recombination/class-switch recombination and tumor-suppressive checkpoint function, while growth/neurodevelopmental pathways (more sensitive to replication stress) are still impaired. This is a hypothesis, not established by direct mechanistic study, and the emerging bone-marrow-failure phenotype in some patients (Takagi 2023, Chansel-Da Cruz 2020) shows this attenuation is allele-dependent and incomplete.

Molecular pathways: DNA damage response (DDR) / ATM-CHK2 checkpoint signaling pathway (KEGG hsa03450 Non-homologous end-joining; hsa03440 Homologous recombination; Reactome "DNA Double-Strand Break Repair").

Cellular processes (GO terms): - GO:0006302 double-strand break repair - GO:0000724 double-strand break repair via homologous recombination - GO:0007049 cell cycle / GO:0000077 DNA damage checkpoint signaling - GO:0006281 DNA repair - GO:0004725 (not applicable here; relevant to other modules) — instead: GO:0005524 ATP binding (RAD50 ATPase activity)

Protein dysfunction: Predominantly loss of function via destabilization/truncation; one well-characterized allele (E1035Δ) demonstrates a separation-of-function mechanism — selective loss of DNA-end-resection/replication-fork functions with preserved ATM-signaling function, attributed to disruption of coiled-coil heptad-repeat conformational dynamics (PMC7788285).

Metabolic changes: Not specifically documented for NBSLD.

Immune system involvement: Variable and allele-dependent — absent in "classic" NBSLD (Waltes 2009, Ragamin 2020), but documented in an emerging subset with bone marrow failure, B-lymphocyte deficiency, and impaired T-lymphopoiesis (Chansel-Da Cruz 2020: "virtual absence of B lymphocytes; impaired T lymphopoiesis"; Takagi 2023 patient with immunodeficiency).

Tissue damage mechanisms: Genome instability/replication stress in high-turnover progenitor pools (neural, hematopoietic, germline) rather than classical oxidative/ischemic/fibrotic injury.

Biochemical abnormalities: Defective RAD50 ATPase/Zn-hook function; failure of ATM autophosphorylation (Ser1981) and substrate phosphorylation after ionizing radiation.

Suggested cell types (CL terms) and biological processes (GO terms) for pathophysiology nodes: - CL:0000034 stem cell / CL:0000037 hematopoietic stem cell (bone-marrow-failure subset) - CL:0000542 lymphocyte / CL:0000236 B cell / CL:0000084 T cell (immunodeficiency subset) - CL:0011020 neural progenitor cell (microcephaly mechanism, by analogy) - GO:0000724 double-strand break repair via homologous recombination - GO:0031573 intra-S DNA damage checkpoint signaling - GO:0006974 DNA damage response

Molecular profiling / advanced technologies: No transcriptomic, proteomic, metabolomic, single-cell, or spatial-omics datasets specific to human NBSLD patient tissue have been published (GEO/ArrayExpress search did not return disease-specific datasets); available molecular data are limited to targeted Western blot, immunofluorescence (MRN foci), and functional cellular assays (RDS, chromosome breakage, ATM-substrate phosphoblotting) in patient-derived fibroblasts/lymphoblasts.

7. Anatomical Structures Affected

Organ level: - Primary: Craniofacial skeleton/brain (microcephaly, dysmorphic facies), skeletal system (growth plates — short stature, brachydactyly/clinodactyly), skin (café-au-lait macules) - Secondary: Inner ear (sensorineural hearing loss), cardiac conduction system (WPW pattern in one case), cerebellum/craniocervical junction (Chiari malformation), ocular (hyperopia, cataract in one allele), hematopoietic system and immune organs (bone marrow, lymphoid tissue — in the emerging severe subset), testes (cryptorchidism in one case) - Body systems: Musculoskeletal, nervous, integumentary, and — in a subset — hematologic/immune systems

Tissue and cell level: - Neural progenitor cells and developing cerebral cortex (microcephaly) - Growth-plate chondrocytes/osteoblasts (short stature, skeletal dysmorphism) - Cochlear hair cells / auditory neuroepithelium (sensorineural hearing loss) - Hematopoietic stem/progenitor cells, B and T lymphocytes (bone marrow failure subset) - Fibroblasts (the primary experimental cell type used for all functional/cellular studies — radiosensitivity, MRN foci, RDS assays)

Subcellular level (GO Cellular Component): - GO:0005634 nucleus (site of MRN complex action) - GO:0000784 nuclear chromosome, telomeric region (MRN telomere maintenance role) - GO:0035861 site of double-strand break

Localization (UBERON): - UBERON:0000955 brain; UBERON:0001851 cortex - UBERON:0001690 ear / UBERON:0001846 cochlea - UBERON:0002371 bone marrow - UBERON:0002370 thymus (T-lymphopoiesis) - UBERON:0000178 blood - Bilateral/symmetric involvement typical (microcephaly, growth failure); no lateralization reported.

8. Temporal Development

Onset: Congenital/prenatal onset — severe intrauterine growth restriction and microcephaly are present from birth; postnatal growth restriction and microcephaly (often progressive) continue through childhood. This places NBSLD onset squarely in the neonatal/congenital category (OMIM lists "age of onset in the neonatal period").

Progression: - Growth/head circumference: Progressive postnatal microcephaly documented in longitudinal case follow-up (e.g., patient followed to age 15 showed head circumference declining further below population norms). - Neurocognitive: Notably stable, non-progressive course in the best-documented patients — "no decline of intellectual or motor functions has been observed," and ataxia (when present) is described as "slight and nonprogressive," a key distinguishing feature from the progressive cerebellar degeneration of ATLD. - Hematologic/immune (severe subset): Progressive bone marrow failure has been documented in at least one patient, evolving over time (age 7 onward) to aplastic anemia — a distinct and more severe disease trajectory. - Disease course pattern: Predominantly stable/static dysmorphic-growth phenotype punctuated by an occasional progressive hematologic/immunologic trajectory in a minority of alleles. - Duration: Chronic, lifelong condition; the oldest reported patient was followed to at least 23 years of age (Waltes et al. 2009) without malignancy.

Patterns: - No spontaneous remission described (structural/growth features are static; hematologic decline in the severe subset does not remit spontaneously). - Critical periods: Prenatal and early postnatal periods are the critical windows for growth/head-circumference deficits, given congenital onset; genetic evaluation prior to any elective growth-hormone therapy is now explicitly recommended as a "critical intervention window" issue, since GH was started empirically (without genetic workup) in the 2026 Chinese case before RAD50 deficiency was recognized.

9. Inheritance and Population

Epidemiology: Prevalence <1 per 1,000,000 (OMIM/Orphanet estimate); incidence not separately calculable given fewer than 10 total published patients. This contrasts sharply with classic NBS, whose Slavic founder mutation gives regional prevalence up to >20 per 1,000,000 in parts of Belarus/Ukraine (PMC7819964).

Inheritance pattern: Autosomal recessive (AR); all reported cases are homozygous or compound heterozygous for biallelic RAD50 variants.

Penetrance: Presumed complete for the core growth/microcephaly phenotype in biallelic carriers (all reported patients manifest disease); however, phenotypic severity varies considerably by allele (from mild "classic" NBSLD to severe bone-marrow-failure phenotypes), suggesting variable expressivity driven largely by hypomorphic vs. separation-of-function vs. near-null allele combinations rather than incomplete penetrance per se.

Genetic anticipation: Not described/applicable (not a repeat-expansion disorder).

Germline mosaicism: Not specifically reported for RAD50-NBSLD.

Founder effects: None established (contrast NBN c.657del5 Slavic founder mutation, carrier frequency 0.5–1%, PMC5148078). Each RAD50-NBSLD family reported carries private variants; the disorder has been documented in Turkish (consanguineous), European, and Chinese families, arguing against a single founder population.

Consanguinity: A major risk factor in reported cases — e.g., the second reported patient (Ragamin et al. 2020) was homozygous for a novel variant, born to consanguineous Turkish parents.

Carrier frequency: Not established at a population level (each variant is individually ultra-rare; gnomAD MAF ~1.07×10⁻⁴ heterozygous-only for one reported allele).

Population demographics: Reported patients span European (Dutch/German, original 2009 report), Turkish, and Chinese ancestries — no clear ethnic clustering, unlike NBS's strong Slavic association.

Geographic distribution: No endemic region identified; cases are geographically scattered case reports (Netherlands/Germany, Turkey, China, Japan [Takagi/Kanegane group]).

Sex ratio: Both male and female patients reported (e.g., 23-year-old female in Waltes 2009; 15-year-old female in Ragamin 2020; male patients in the Chinese/GH case reports) — no established sex predilection given small numbers.

Age distribution: Diagnoses reported from infancy through the mid-20s in the oldest documented patient; disease is lifelong from a congenital onset.

10. Diagnostics

Clinical laboratory tests: - Radioresistant DNA synthesis (RDS) assay — the key functional diagnostic test, measuring failure of DNA synthesis suppression after ionizing radiation exposure in patient fibroblasts/lymphocytes; abnormal (elevated) RDS is shared with ataxia-telangiectasia, NBS, and ATLD, so it is not RAD50-specific by itself. - Chromosomal breakage/instability analysis (metaphase cytogenetics) — variably abnormal. - Clonogenic radiosensitivity assay (colony survival after ionizing radiation) — demonstrates hypersensitivity. - Western blot for RAD50/MRE11/NBS1 protein levels in patient-derived fibroblasts — shows absent/reduced RAD50 with secondary reduction of complex partners; this is the most disease-specific functional readout. - Immunofluorescence for MRN nuclear foci after DNA damage — shows failure of focus formation. - ATM-pathway phosphoprotein assays — absent/reduced phospho-CHK2 (Ser19), phospho-KAP1/TRIM28 (Ser824) post-irradiation.

Biomarkers: No circulating serum/plasma biomarker exists; diagnosis relies on cellular functional assays plus molecular genetics. (For context, classic NBS diagnostic workup also includes serum immunoglobulin levels and lymphocyte subsets — largely normal in NBSLD, distinguishing it.)

Imaging: Brain MRI recommended over CT (radiosensitivity) — has shown Chiari malformation in at least one patient; skeletal survey for growth/skeletal dysmorphism; ionizing-radiation imaging (X-ray, CT) should be minimized given cellular radiosensitivity.

Functional/electrophysiology tests: Audiometry (identified 90 dB bilateral sensorineural hearing loss in one patient); ECG (identified WPW pattern in one patient, without arrhythmia).

Biopsy/histopathology: Not a standard diagnostic requirement; disease diagnosis relies on fibroblast functional assays rather than tissue biopsy/histopathology.

Genetic testing: - Recommended approach: Given phenotypic overlap with NBS/ATLD/other microcephaly-DNA-repair disorders, a multi-gene panel covering RAD50, NBN, MRE11A, ATM, and related chromosomal-instability genes is the recommended first-line approach, escalating to whole-exome sequencing (WES) — which is how essentially all reported NBSLD cases have actually been solved (trio-based WES in the recent Chinese case; WES in the Takagi 2023 case). - Single-gene RAD50 sequence analysis (all coding exons) is commercially available (NCBI GTR test ID 578298, ncbi.nlm.nih.gov/gtr/tests/578298). - Chromosomal microarray/karyotype/FISH: Not primary diagnostic tools (NBSLD is a sequence-level, not copy-number, disorder), though karyotype may show acquired instability. - Whole genome sequencing (WGS): Not specifically reported as used but would capture splice-region variants like c.2524G>A that WES might miss without careful splice analysis. - Functional RNA studies (RT-PCR): Essential for confirming splice-site variant pathogenicity (as done for c.2524G>A, revealing exon-15-skipping and missense transcripts).

Clinical diagnostic criteria: No formal consensus diagnostic criteria society guideline exists (disease is too rare); working diagnosis is based on the combination of (1) severe pre/postnatal growth failure + microcephaly, (2) laboratory evidence of radiosensitivity/RDS, and (3) biallelic RAD50 variants, with exclusion of the immunodeficiency/cancer features that would instead suggest classic NBS or a more severe RAD50-null/bone-marrow-failure phenotype.

Differential diagnosis: - Classic Nijmegen breakage syndrome (NBN mutations) — distinguished by severe combined immunodeficiency and high lymphoid malignancy risk - Ataxia-telangiectasia-like disorder (MRE11A mutations) — distinguished by progressive cerebellar ataxia/neurodegeneration, typically without microcephaly - Ataxia-telangiectasia (ATM mutations) - Other primary microcephaly syndromes (MCPH genes) - Seckel syndrome and other growth-failure/microcephaly syndromes - Fanconi anemia and other bone-marrow-failure syndromes (relevant differential for the severe subset with cytopenias)

Screening: No newborn screening program exists (disease too rare, no biochemical marker). Prenatal diagnosis/carrier screening is feasible via targeted molecular testing once a familial variant is known (as for any AR Mendelian disease), particularly relevant given documented consanguinity in some families.

11. Outcome / Prognosis

Survival/mortality: No formal survival statistics exist given the tiny cohort. The oldest well-documented patient survived to at least 23 years without malignancy (Waltes et al. 2009); a second patient was followed to 15 years without malignancy (Ragamin et al. 2020). This suggests a substantially better long-term prognosis than classic NBS, where malignancy (chiefly B-cell lymphoma) is the dominant cause of premature mortality, with lymphoid cancer developing in a large proportion of NBS patients by young adulthood.

Morbidity/function: Growth failure (short stature), microcephaly, and mild learning difficulties are the chronic morbidities; hearing loss and skeletal anomalies add functional burden in some patients. Critically, no progressive neurological decline has been documented in the core NBSLD phenotype (contrasting with ATLD's progressive ataxia and NBS's neurodevelopmental concerns).

Disease course/complications: - Core NBSLD: stable, non-progressive intellectual/motor course; growth and craniofacial features are static congenital findings. - Severe subset: progressive bone marrow failure (aplastic anemia), recurrent infection risk from B/T lymphopenia, early cataract — a materially worse prognosis paralleling inherited bone-marrow-failure syndromes. - Unknown/theoretical malignancy risk: because RAD50 is a DNA-repair/tumor-suppressor-pathway gene and its paralogs (NBN, MRE11A) confer cancer predisposition, authors explicitly recommend managing NBSLD patients with NBS-level cancer surveillance vigilance despite the absence of confirmed malignancy in the literature to date — an important prognosis caveat: absence of evidence for cancer risk (small n, sometimes short follow-up) is not evidence of absence.

Prognostic factors: Allele type appears to be the dominant driver of prognosis — near-null/complex-destabilizing alleles associate with the "classic" milder NBSLD phenotype in some patients, whereas certain alleles (e.g., RAD50 E1035Δ separation-of-function, or the compound heterozygous genotype in the Takagi 2023 patient) associate with a bone-marrow-failure/immunodeficiency trajectory — suggesting genotype-phenotype correlation exists but is not yet fully mapped across the small number of known alleles.

Prognostic biomarkers: None validated; residual RAD50/MRE11/NBS1 protein level and degree of ATM-signaling preservation are plausible (but unvalidated) prognostic correlates based on the mechanistic literature.

12. Treatment

There is no disease-specific or curative therapy for RAD50-NBSLD; management is supportive and extrapolated largely from classic NBS protocols, adjusted for the (usually) milder immune phenotype.

Pharmacotherapy: - No approved pharmacotherapy targets the RAD50/MRN defect itself. - Recombinant human growth hormone (rhGH) has been used off-label for short stature — a 2026 case report (Frontiers in Endocrinology) documented 5 years 9 months of rhGH (0.15–0.2 IU/kg/day, IGF-1-titrated) in a RAD50-NBSLD patient, improving height from −3.35 SD to −1.28 SD (average 7.3 cm/year growth velocity) with no adverse reactions observed and no tumor evidence at 5-year post-discontinuation follow-up. However, the authors explicitly flag this as an "unplanned" treatment response (GH was started before genetic diagnosis) and caution that genetic evaluation should precede GH therapy in syndromic short stature given the theoretical malignancy risk associated with impaired DNA-repair capacity — a risk-benefit issue specific to DNA-repair-deficiency syndromes (GH/IGF-1 signaling is mitogenic). - IVIG replacement and prophylactic antibiotics — used empirically in the immunodeficient/bone-marrow-failure subset, extrapolated from NBS management (not specifically trialed in NBSLD but standard for the phenotypic overlap group).

Advanced therapeutics: - Hematopoietic stem cell transplantation (HSCT) — not reported specifically for RAD50-NBSLD in the literature reviewed, but would be the standard consideration for the bone-marrow-failure subset (by analogy to other inherited BMF syndromes and to NBS management for severe immunodeficiency), with the caveat that conditioning-regimen radiosensitivity would require radiation- and alkylator-reduced conditioning protocols, again by analogy to ATM/MRN-pathway-deficient HSCT literature. - Gene therapy, cell therapy (beyond HSCT), RNA-based therapies, and targeted molecular therapies have not been reported for this disorder.

Surgical/interventional: No disease-specific surgical intervention; management of individual complications (e.g., cataract extraction, Chiari decompression if symptomatic) would follow standard surgical practice, with radiologic planning shifted toward non-ionizing modalities where feasible.

Supportive/rehabilitative care: - Speech/motor developmental therapy (physical therapy, occupational therapy, speech therapy) for developmental delay - Hearing aids/audiologic support for sensorineural hearing loss - Nutritional support for growth failure - Multidisciplinary genetics, endocrinology, hematology/immunology, and neurology follow-up

Experimental treatments: No registered clinical trials specific to RAD50-NBSLD were identified in this search (ClinicalTrials.gov has no RAD50-NBSLD-specific studies; broader NBS-related trials focus on classic NBN-mutated NBS, e.g., cancer surveillance and antioxidant studies).

Treatment outcomes/adverse events: The only quantified treatment-outcome data available are from the rhGH case (above) — no other systematic treatment-response data exist.

Treatment strategy / algorithm (extrapolated from NBS + expert case-report recommendations): 1. Confirm molecular diagnosis (WES/panel) before initiating any growth-promoting or immunomodulatory therapy. 2. Avoid ionizing-radiation-based imaging; prefer MRI/ultrasound. 3. Baseline and periodic assessment of growth, immune function (immunoglobulins, lymphocyte subsets), cognitive development, and hematologic parameters (given emerging BMF phenotype). 4. Consider rhGH for growth failure only after genetic counseling on theoretical cancer-risk trade-offs. 5. Empiric cancer surveillance (physical exam, blood counts, imaging as tolerated) analogous to NBS protocols, pending disease-specific evidence. 6. Avoid live vaccines if any immunodeficiency is confirmed (extrapolated from NBS guidance).

Suggested MAXO terms: - MAXO:0000647 chemotherapy — not applicable (no current chemo indication) - MAXO:0010039 organ/hematopoietic transplantation — for HSCT in BMF subset - MAXO:0000011 physical therapy; MAXO:0000930 speech therapy; MAXO:0001351 occupational therapy — for developmental support - MAXO:0000950 supportive care - Pharmacotherapy: NCIT:C15986 (generic) with therapeutic_agent bound to CHEBI/NCIT term for somatropin (recombinant human growth hormone)

13. Prevention

Primary prevention: Not applicable in the traditional sense (Mendelian genetic disease); the only "primary prevention" lever is genetic/reproductive counseling for known carrier couples (especially consanguineous families) to inform reproductive decision-making, and preimplantation genetic diagnosis (PGD) or prenatal testing once a familial pathogenic variant is identified.

Secondary prevention (early detection): Early molecular diagnosis via WES/panel testing in any infant presenting with severe pre/postnatal growth restriction plus congenital microcephaly (particularly without the severe immunodeficiency/infection pattern that would suggest classic NBS) allows earlier initiation of radiation-avoidance precautions and surveillance.

Tertiary prevention: Avoidance of ionizing radiation exposure (diagnostic and therapeutic) is the single most actionable, disease-specific preventive measure, given documented cellular radiosensitivity — this is analogous to, but with less certain magnitude of risk than, the well-established radiation-avoidance guidance for classic NBS and ataxia-telangiectasia.

Immunization: No NBSLD-specific vaccine guidance published; for the subset with confirmed immunodeficiency, standard primary-immunodeficiency vaccine precautions (avoidance of live vaccines pending immune assessment) would apply by extrapolation from NBS/PID management, not from disease-specific trial data.

Screening/genetic counseling: Carrier screening and cascade testing in relatives of an index case; genetic counseling emphasizing autosomal recessive inheritance (25% recurrence risk per pregnancy for carrier couples) and — as newly flagged by the 2026 GH case report — counseling before elective growth-promoting therapy given the theoretical mitogenic/malignancy-risk interaction with underlying DNA-repair deficiency.

Behavioral interventions / public health / prophylaxis: Not applicable beyond the radiation-avoidance and infection-precaution measures already described; this is not a disease with population-level environmental or infectious prevention levers.

14. Other Species / Natural Disease

Taxonomy: RAD50 is deeply evolutionarily conserved from yeast to human (NCBITaxon:9606 Homo sapiens for the human disease; orthologs exist across essentially all eukaryotes given the ancient, essential nature of DSB repair).

Naturally occurring disease in other species: No naturally occurring veterinary RAD50-deficiency syndrome analogous to human NBSLD has been reported in companion animals or wildlife (OMIA search did not surface a RAD50-associated natural veterinary disease); this contrasts with many other Mendelian disease genes that do have recognized veterinary/naturally-occurring counterparts.

Comparative biology / orthologous genes: - Mouse: Rad50 (MGI:109292) - Yeast: RAD50 (the original gene discovery organism — S. cerevisiae radiation-sensitive mutant screens) - Medaka fish: rad50 (used for an engineered disease model, see below) - Drosophila: Mre11-Rad50-Nbs ortholog complex (implicated in telomere capping during embryogenesis, PMID:19520832)

Transmission: Not applicable (non-infectious, non-zoonotic genetic disease).

15. Model Organisms

Genetic models: - Mouse complete Rad50 knockout: Embryonic lethal — a null Rad50 mutation, which presumably fully abrogates the structural role of the Mre11 complex, results in early embryonic death, underscoring RAD50's essential role in genome maintenance and precluding a viable full-knockout model of human disease. - Rad50^S/S hypomorphic mice (the disease-relevant model): a separation-of-function allele preserving MRN complex integrity but reducing function. Phenotype: partial embryonic lethality; shortened lifespan; progressive loss of germline and hematopoietic cells; death from hematopoietic failure by ~3 months of age; growth defects; cancer predisposition; cultured cells show increased spontaneous apoptosis and chromosomal instability; telomere-maintenance defects due to loss of MRN integrity (PMID:12208847, genesdev.cshlp.org/content/16/17/2237). This model recapitulates the cancer-predisposition and bone-marrow-failure arm of the human phenotypic spectrum (i.e., the severe subset) better than the "classic" milder human NBSLD presentation, illustrating that mouse hypomorphic models may better model the severe end of the human allelic spectrum. - Medaka fish CRISPR/Cas9 rad50 2-bp-deletion model (PLOS ONE 2023, PMC10129005): heterozygous rad50Δ2/+ medaka developed tumors in 8/10 fish and had reduced median survival (54.2 ± 2.6 weeks vs. 65.7 ± 1.1 weeks in controls); homozygous rad50Δ2/Δ2 fish were semi-lethal and reproduced most major ataxia-telangiectasia phenotypic features including ataxia — providing a tractable, transparent vertebrate model for both the cancer-predisposition and neurological aspects of MRN-complex disease, though notably modeling an AT-like rather than a growth-failure/microcephaly phenotype.

Model characteristics — recapitulation vs. limitations: - Both the mouse Rad50S/S and medaka rad50 models capture the cancer predisposition and hematopoietic/genome-instability dimensions of RAD50 dysfunction robustly. - Neither model fully recapitulates the core "classic" human NBSLD phenotype (severe growth restriction, progressive but non-degenerative microcephaly, absence of cancer/immunodeficiency) — a human-model mismatch: the animal models instead better represent the more severe bone-marrow-failure/malignancy-prone end of the human allelic spectrum, or an AT-like neurological phenotype, rather than the mild "classic" NBSLD growth/craniofacial phenotype first described by Waltes et al. This gap is consistent with the broader observation that complete or near-complete RAD50 loss is poorly tolerated in mammals (embryonic lethal), so viable human patients necessarily carry partial-function hypomorphic alleles whose precise residual activity is difficult to reproduce precisely in animal knock-in models. - Applications: These models remain valuable for studying MRN-complex-dependent tumor suppression, hematopoietic stem cell maintenance, ATM-pathway biology, and telomere maintenance mechanisms relevant to the RAD50-disease spectrum broadly.

Cellular/in vitro models: Patient-derived primary fibroblasts (the dominant experimental system in every published human case report) are used for radiosensitivity, RDS, chromosome-breakage, MRN-focus, and ATM-substrate-phosphorylation assays; no iPSC-derived model of RAD50-NBSLD has been reported.

Resources: MGI (mouse, Rad50 MGI:109292); no dedicated RAD50-NBSLD registry exists in ZFIN/FlyBase/WormBase; IMPC/KOMP conditional-knockout resources for Rad50 exist for research use given the lethality of full constitutive knockout.

Summary Table of Key Ontology Term Suggestions

Sources

• Nijmegen Breakage Syndrome-Like Disorder - MalaCards
• OMIM #613078 - NIJMEGEN BREAKAGE SYNDROME-LIKE DISORDER; NBSLD
• OMIM Clinical Synopsis #613078
• OMIM *604040 - RAD50 DOUBLE-STRAND BREAK REPAIR PROTEIN; RAD50
• Orphanet: Nijmegen breakage syndrome-like disorder (ORPHA240760)
• Orphanet: Nijmegen breakage syndrome (ORPHA647)
• Monarch Initiative: MONDO:0013118
• NCBI MedGen C2751318
• NCBI GTR RAD50 sequence test
• Waltes et al. 2009, "Human RAD50 Deficiency in a Nijmegen Breakage Syndrome-like Disorder" (Am J Hum Genet), PMID:19409520
• Ragamin et al. 2020, "Human RAD50 deficiency: Confirmation of a distinctive phenotype" (Am J Med Genet A), PMC7318339
• Chansel-Da Cruz et al. 2020, RAD50 E1035Δ separation-of-function mutation, PMC7788285
• Takagi/Kanegane et al. 2023, "Bone Marrow Failure and Immunodeficiency Associated with Human RAD50 Variants" (J Clin Immunol)
• EurekAlert press release on Takagi/Kanegane RAD50 variant discovery
• 2026 ScienceDirect: "Expanding the mutational spectrum of RAD50: a case report... in a Chinese child"
• 2026 Frontiers in Endocrinology: "Novel RAD50 variants lead to NBS-like disorder and unplanned rhGH treatment response"
• Redeker et al. 2025, "RAD50 missense variants differentially affect the DNA damage response and mitotic progression" (FEBS Letters), PMC12720227
• PeerJ 2020, "In silico analysis on the functional and structural impact of Rad50 mutations"
• GeneCards: RAD50 Gene
• RAD50, an SMC family member with multiple roles in DNA break repair (PMC4494100)
• MRE11-RAD50-NBS1 keystone complex review, PMID:17713585
• Ataxia-telangiectasia-like disorder MRE11A family, PMC6283458
• Two unrelated patients with MRE11A mutations and NBS-like severe microcephaly, PubMed 21227757
• OMIM #251260 - Nijmegen Breakage Syndrome
• The Slavic NBN Founder Mutation: A Role for Reproductive Fitness?, PMC5148078
• Geographical Distribution, Incidence, Malignancies and Outcome of 136 Eastern Slavic NBS Patients, PMC7819964
• RAD50 and NBS1 are breast cancer susceptibility genes, PMC3006189
• Germline pathogenic variants in MRN genes and cancer predisposition, meta-analysis 2024, IJC
• RAD50 zinc hook LoF variants and familial esophageal squamous cell carcinoma, PMC8472384
• Cancer predisposition and hematopoietic failure in Rad50(S/S) mice, PMID:12208847
• A rad50 germline mutation induces tumorigenesis and ataxia-telangiectasia phenotype in medaka, PMC10129005
• MGI Rad50 mouse gene detail (MGI:109292)